IL1A as A Drug Target and Biomarker for Diseases (G3552)

Target Name: IL1A

NCBI ID: G3552

IL1A

IL1A as A Drug Target and Biomarker for Diseases

IL-1 Alpha is a protein that is expressed in a variety of tissues throughout the body. It is a cytokine that is involved in the immune response and has been implicated in a number of diseases, including inflammation, fibrosis, and cancer.

One of the things that makes IL-1伪 an attractive drug target is its role in the development of autoimmune diseases. IL-1伪 is a key mediator of the inflammatory response, and it has been implicated in the development of rheumatoid arthritis, lupus, and other autoimmune diseases.

In addition to its role in autoimmune diseases, IL-1伪 is also involved in the regulation of pain and inflammation. It has been shown to play a key role in the development of pain sensitivity and the regulation of pain perception.

Another potential drug target for IL-1伪 is its role in the regulation of cell survival. IL-1伪 has been shown to promote the survival of cancer cells and to inhibit the death of cancer cells that have become resistant to chemotherapy. This makes it an attractive target for cancer therapies that are designed to extend the lives of patients.

In addition to its potential as a drug target, IL-1伪 is also a potential biomarker for a number of diseases. For example, high levels of IL-1伪 have been shown to be associated with the development of a variety of diseases, including heart disease, diabetes, and cancer. This makes it an potential indicator of the overall health of an individual and a potential target for diagnostic tests.

Overall, IL-1伪 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role and to develop effective therapies that can exploit its properties.

Protein Name: Interleukin 1 Alpha

Functions: Cytokine constitutively present intracellularly in nearly all resting non-hematopoietic cells that plays an important role in inflammation and bridges the innate and adaptive immune systems (PubMed:26439902). After binding to its receptor IL1R1 together with its accessory protein IL1RAP, forms the high affinity interleukin-1 receptor complex (PubMed:2950091, PubMed:17507369). Signaling involves the recruitment of adapter molecules such as MYD88, IRAK1 or IRAK4 (PubMed:17507369). In turn, mediates the activation of NF-kappa-B and the three MAPK pathways p38, p42/p44 and JNK pathways (PubMed:14687581). Within the cell, acts as an alarmin and cell death results in its liberation in the extracellular space after disruption of the cell membrane to induce inflammation and alert the host to injury or damage (PubMed:15679580). In addition to its role as a danger signal, which occurs when the cytokine is passively released by cell necrosis, directly senses DNA damage and acts as signal for genotoxic stress without loss of cell integrity (PubMed:26439902)

The "IL1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets